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Background: Over the last decade network enrichment analysis has become popular in computational systems
biology to elucidate aberrant network modules. Traditionally, these approaches focus on combining gene expression
data with protein-protein interaction (PPI) networks. Nowadays, the so-called omics technologies allow for inclusion of
many more data sets, e.g. protein phosphorylation or epigenetic modifications. This creates a need for analysis methods
that can combine these various sources of data to obtain a systems-level view on aberrant biological networks.
Results: We present a new release of KeyPathwayMiner (version 4.0) that is not limited to analyses of single omics data
sets, e.g. gene expression, but is able to directly combine several different omics data types. Version 4.0 can further
integrate existing knowledge by adding a search bias towards sub-networks that contain (avoid) genes provided in a
positive (negative) list. Finally the new release now also provides a set of novel visualization features and has been
implemented as an app for the standard bioinformatics network analysis tool: Cytoscape.
Conclusion: With KeyPathwayMiner 4.0, we publish a Cytoscape app for multi-omics based sub-network extraction. It
is available in Cytoscape’s app store http://apps.cytoscape.org/apps/keypathwayminer or via http://keypathwayminer.
mpi-inf.mpg.de.
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The massive increase in high-quality and publicly available
biological databases over the last decade has led to network
enrichment analysis becoming a comprehensively used
approach to study entire lists of proteins and the effect of
their interactions instead of single functional analyses. The
goal is to identify differentially expressed sub-networks in
an organism’s interaction network. These sub-networks are
commonly referred to as active modules [1,2] and key
pathways [3,4], for instance.
Most de novo network enrichment methods have tra-
ditionally been focusing on combining gene expression
microarray data with PPI networks. Advancements in high
throughput techniques have made it possible to produce* Correspondence: nalcaraz@imada.sdu.dk
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unless otherwise stated.various omics datasets in addition to expression data, for
example DNA-methylation and other epigenetic modifica-
tions, single nucleotide polymorphisms (SNPs), gene copy
number variations (CNVs), or protein expression and
post-translational modifications, amongst others. We seek
to integrate all of the available omics data measured in a
certain experiment to account for the entangled nature of
biological process regulation. Recently, some attempts
have been made to combine multiple omics datasets to
provide an integrative enrichment platform, e.g. [5,6].
However, there is no app available for the combined
analysis of multiple omics data sets together with bio-
logical networks in Cytoscape, which is the standard tool
for bioinformatics systems biology network analysis [7].
Previously, we have developed KeyPathwayMiner, a
method to identify aberrant sub-networks based on
combining a single omics study and a PPI network in
Cytoscape release series 2. This was accomplished by aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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torial optimization problem: Extraction of a maximal
connected sub-network where all nodes but at most k
are differentially expressed (deregulated) in all patients/
cases but at most l [4]. KeyPathwayMiner comes with a
set of heuristics (ant colony optimization), as well as
exact (fixed-parameter) algorithms that combine a statis-
tical evaluation and discretization on the omics data and
PPI network. The KeyPathwayMiner strategy was
explained and evaluated in detail in [4,8,9].
Here, we account for compatibility with the new
Cytoscape release 3 [10], which required redesign of the
previous app code to comply with the new API library.
With the new KeyPathwayMiner 4.0 app, we also imple-
mented a set of extensions to the previous version,
which broaden the applicability of KeyPathwayMiner
and increases its usability. The usual workflow through
KeyPathwayMiner is depicted in Figure 1. New features
are highlighted in blue color. We added functionality to
(1) provide multi-dataset support, (2) integrate existing
knowledge, and (3) enhance visualization and ease of
parameter setting. As an application case, we describe a
colorectal cancer case study that makes use of the multi-
omics feature by integrating gene expression and DNA
methylation data. We also provide step-by-step instructions
on how to use KeyPathwayMiner 4.0 in Additional file 1.Figure 1 KeyPathwayMiner workflow. The previous versions of KeyPathw
KeyPathwayMiner 4.0 can integrate multiple datasets and provides advance
highlighted (blue borders).Implementation
Combining multiple omics data sets
We assume discretized omics data sets, i.e. they have
been statistically transformed into indicator matrices. An
indicator matrix describes if a specific gene/protein is
significantly altered in its expression for a specific case
compared to a set of controls. This step largely depends
on the study design and the applied omics technologies.
It has to be performed for each data type individually.
While integrating the different omics datasets the
number of cases/samples in each of the studies has to be
accounted for. If all omics studies come from the same
cases and, thus, have the same number of cases, one
indicator matrix can be generated for each study. After-
wards, all these matrices are combined into a single one
by a set of particular criteria. Consider a gene P, which is
active in case Q1 (expression matrix M1), and the same
gene is not active in case Q2 (expression matrix M2). One
may apply a logical “OR”, for instance, such that P counts
as active in the combined matrix Mc =M1 OR M2.
However, for unconnected datasets, where the number
of cases doesn’t match (e.g. different sample sets used for
expression data and methylation data), KeyPathwayMiner
was extended to accept multiple matrices. The user
now can specify the maximum number of non-active
cases (L exceptions) for each matrix in order for eachayMiner allowed network enrichment with a single dataset.
d visualization. The new features of KeyPathwayMiner 4.0 are
Alcaraz et al. BMC Systems Biology 2014, 8:99 Page 3 of 6
http://www.biomedcentral.com/1752-0509/8/99gene to be considered active. For simplicity, let’s assume
we have two matrices M1 and M2 with differing number
of cases. Then parameters L1 for M1 and L2 for matrix
M2 can be specified. After selecting the desired logical
connector, for example the logical “AND”, then a gene will
be considered active if it’s corresponding entry in M1 con-
tains at most L1 non-active cases AND it’s corresponding
entry in M2 contains at most L2 non-active cases. Finally,
KeyPathwayMiner 4.0 will then scan for maximal con-
nected sub-graphs where all nodes but at most K are
active in all but L1 cases inM1 and L2 cases in M2.
The KeyPathwayMiner 4.0 app now offers a graphical
user interface to apply logical connectors (AND, OR, XOR)
to merge the data sets (see Figure 2 for an example, as
applied on the colorectal cancer application case), to pro-
ject them on the network, and to perform the enrichment.
Integration of prior knowledge
We now offer text fields to input two lists of node IDs, a
positive and a negative one. The nodes in the positive
list will be treated as non-exception nodes by the
algorithms and will bypass the parameter constraints.
Therefore, the nodes specified in the positive list are
more likely to pop up in a solution, i.e. the list of
deregulated sub-networks (key pathways). Note that
positive lists may generally lead to larger key pathways.
Inversely, the nodes from the negative list will always be
treated as exception nodes and are less likely to be present
in a solution. Thus, these lists will bias the search
algorithms to prefer or avoid a specified set of genes/pro-
teins (i.e. nodes). This feature can be used to reflect existing
background knowledge. Genes or proteins that are known
to be unrelated may be avoided. Solutions containing nodes
known to play a role in a certain disease, for instance, may
be favored.
Enrichment-specific visualization
Previous software versions presented the results as a list
of deregulated key pathways for one set of parameters.Figure 2 Combined formula for the colorectal cancer case study. We
aberrant gene expression as well as irregular DNA methylation.The new app comes with two improvements. First, it
can pre-compute solutions for systematically varying
combinations of the main parameters k and l. Second, to
assist in parameter optimization, we implemented a
node-coloring scheme such that the color intensity of a
node varies with regard to the number and size of key
pathways containing it. After the pathway search is
complete, the user can see darker and lighter blue areas in
the Cytoscape visualization of the network. By clicking on
one combination, the user can visually inspect the effect
of changing parameters on the size (and location) of the
reported sub-networks (the higher k and l, the bigger the
blue areas in the network). The node coloring, thus, visually
supports the fine-tuning of optimal parameter combina-
tions. Several other visualization schemes are implemented
in the app (not discussed here).
Case study
In the following sections, we describe a case study, to
introduce the utility of KeyPathwayMiner 4.0 and to
explain how the Cytoscape app can be used to analyze
multiple omics datasets conjointly and together with a
network given and displayed with Cytoscape release 3.
Additional file 1 provides a step-by-step description on
how to install Cytoscape, KeyPathwayMiner, and how to
analyze the dataset (a sample file and application case is
provided with the additional material). For further infor-
mation, please refer to the web site (http://keypathway
miner.mpi-inf.mpg.de) and click at “App for Cytoscape
3” to receive a detailed description of all features. This
page will be kept up-to-date and describe future soft-
ware updates and improvements.
Background
In this case study, we used the new KeyPathwayMiner
4.0 app to perform a multi-omics analysis of colorectal
cancer. Colorectal cancer accounts for high cancer mor-
tality and morbidity [11]. We used gene expression and
DNA methylation data available in public domain tocombined the four matrices such that the key pathways represent
Figure 3 Largest key pathway obtained for the colorectal cancer case study. It consists of 35 proteins. The colorectal cancer associated
genes are highlighted with red border. PI3K signaling associated genes are highlighted with blue border.
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cancer patients. Epigenetic regulations plays a significant
role in controlling gene expression in cancerous cells
specifically in colorectal cancer [12].
Data & data processing
The protein-protein interaction network
The protein-protein interaction network was obtained
from HPRD [13]. The network consisted of 9,427 nodes
and 36,812 edges (Additional file 2).
OMICs data sets
We downloaded the gene expression data and DNA
methylation data from The Cancer Genome Atlas
(TCGA) [11]. We used the preprocessed data available
at the TCGA data portal: 155 samples and 19 normalTable 1 PI3K signaling associated genes in the key
pathway presented in Figure 3
Gene GO term Source
CBL positive regulation of phosphatidylinositol
3-kinase signaling
Pubmed: 17003487
NGF phosphatidylinositol-mediated signaling Reactome
NTRK1 phosphatidylinositol-mediated signaling Reactome
PIK3R1 phosphatidylinositol 3-kinase signaling Pubmed: 7782332
PTK2 positive regulation of phosphatidylinositol
3-kinase signaling
Pubmed: 15166238samples as gene expression data as well as 291 samples
and 38 normal samples as DNA methylation dataset. For
both these data sets, indicator matrices were computed
by comparing their expression values to the normal sam-
ples. We generated four indicator matrices representing
up/down gene expression and high/low DNA methylation
for each gene in each sample (Additional file 3) and com-
bined them as depicted in Figure 2.
Results
The objective was to identify the signaling component
that is active in most of the samples and has aberrant
DNA methylation as well as aberrant gene expression.
Since DNA-methylation impairs a gene’s transcriptional
potential we connected the four matrices in such a way
that the up-regulation of gene expression is associated
with hypo-methylation and down-regulation of gene
expression is associated with hyper methylation, as
shown in Figure 2.
With this combined formula, we computed the path-
ways using the HPRD protein-protein interaction network
and the following parameters:
 Search algorithm: ACO
 Search strategy: INES
 Node exceptions (K): 25
 Case exceptions (L): 25% of the samples, i.e. 39 in
gene expression and 73 in methylation, respectively
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enriched for genes exhibiting altered expression levels and
altered DNA methylation. The biggest key pathway con-
sisted of 35 genes, as depicted in Figure 3. To investigate
whether the genes in this pathway had a significant role in
colorectal cancer, we used the Ingenuity Pathway analysis
(IPA) database (Ingenuity® Systems, www.ingenuity.com).
We found it contains several colorectal cancer associated
genes, which are highlighted in the network of Figure 3.
Additionally, we identified several PI3K signaling associ-
ated genes in this key pathway (Table 1). PI3K signaling is
over active in colorectal cancer and is a hotspot for thera-
peutic targets [14,15].Summary
The application case described here is meant to illustrate
the applicability of KeyPathwayMiner 4.0 regarding its
ability to identify sub-networks in Cytoscape, which are
compact and possess many differentially active (expressed
and methylated) genes, which are thus likely to be disease-
specific. Note that this application example cannot be
applied “blindly” to any kind of data set in a standard fash-
ion. Data normalization and statistical pre-processing has
to be taken into account for the individual omics data types
and study designs. If given a set of indicator matrices and a
network visualized with Cytoscape, KeyPathwayMiner com-
bines the data and detects maximal aberrant sub-networks
and visualizes them in Cytoscape.Discussion
With KeyPathwayMiner 4.0, we help the Cytoscape
community to break out of the traditional way to analyze
single omics studies together with interaction networks,
by introducing a method that allows for a combined
analysis of various types of omics studies. The new
multi omics features were implemented outside the
more computational intensive optimization steps of the
KeyPathwayMiner algorithms, hence the runtimes
reported [4,8,9] for previous versions of the software
remain unaffected. We provided an example of how
expression and methylation datasets could be combined
in KeyPathwayMiner, however, we leave it up to the user
to determine the best way to connect their different data-
sets. Quantifying the benefit of multi omics data integra-
tion in this context under different scenarios remains an
open problem that we plan to tackle in the near future.
Positive and negative custom node lists enable the
utilization of prior expert knowledge. However, this artifi-
cially induced bias does not guarantee an actual modifica-
tion of the output. Even though the k and l parameters
have intuitive real world implications (noise in the
network, noise in the omics data) it has sometimes been
difficult to set these parameters to suitable values that fit agiven data set. The introduced semi-automated result
inspection method based on node coloring can track and
visualize changes in pathway results according to different
parameter values. The pre-processing, however, may be
computationally intense, depending on user specifica-
tions. Finally, KeyPathwayMiner still works on discretized,
indicator matrices. This leaves statistical pre-processing of
the omics data to the user, as different omics data types
require different normalizations and statistical analyses.
For instance, RNA-seq gene expression data needs differ-
ent statistical treatment than miRNA target enrichments
or protein expression assays.
Conclusion
Like previous versions, KeyPathwayMiner 4.0 solves the
combinatorial optimization problem of extracting maximal
deregulated graphs, but now with advanced features such as
integration of multiple omics data sets, incorporation of
prior expert knowledge, and improved visualization features.
Availability and requirements
 Project name: KeyPathwayMiner 4.
 Project home page: http://keypathwayminer.mpi-
inf.mpg.de, http://apps.cytoscape.org/apps/
keypathwayminer.
 Operating system(s): Platform independent.
 Programming language: Java.
 Other requirements: Java 1.5 or higher, Cytoscape 2.*, 3.*
 License: GNU LGPL.
 Any restriction to use by non-academics: none.
Ethics
No ethical issues declared. No experimental research on
vertebrates or any regulated invertebrates. No research
involving original human subjects, human material, or
human data. We utilize publicly available data sets to
demonstrate KeyPathwayMiner’s functionality.
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Additional file 1: Step-by-step instructions for KeyPathwayMiner 4.0.
Additional file 2: Cytoscape network to be used with the step-by-
step instructions.
Additional file 3: Breast cancer expression files to be used with the
step-by-step instructions.
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